Table 1

Baseline characteristics and prevalence of antimicrobial resistance of study patients

P value
Age (years, mean±SD)61.2±11.561.3±10.40.912
Sex (male/female)106/62103/640.789
BMI (kg/m2, mean±SD)23.9±3.223.9±3.40.979
Disease-associated Helicobacter pylori
 Gastric ulcer18 (10.7%)25 (15.0%)0.244
 Duodenal ulcer23 (13.7%)20 (12.0%)0.639
 ER for gastric neoplasia9 (5.4%)6 (3.6%)0.435
 MALT lymphoma1 (0.6%)0 (0%)0.318
Cigarette smoking38 (22.6%)41 (24.6%)0.677
Alcohol drinking25 (14.9%)29 (17.4%)0.536
Daily use PPI before the trial10 (6.0%)6 (3.6%)0.311
Antimicrobial resistance of H. pylori
 Clarithromycin40 (23.8%)42 (25.1%)0.776
  • BMI, body mass index; ER, endoscopic resection; MALT lymphoma, mucosal-associated lymphoid tissue lymphoma; PPI, proton-pump inhibitor; VAC-triple, vonoprazan, amoxicillin and clarithromycin triple therapy; VA-dual, vonoprazan and amoxicillin dual therapy.